Registering New Drugs for Low-Income Countries: The African Challenge
Author Information
Author(s): Mary Moran, Nathalie Strub-Wourgaft, Javier Guzman, Pascale Boulet, Lindsey Wu, Bernard Pecoul
Hypothesis
What is the best strategy to approve novel drugs for diseases that predominantly affect patients in Africa?
Conclusion
The study suggests that an optimal drug registration approach for Africa should integrate various approval mechanisms to improve the evaluation of safety, efficacy, and quality of drugs for African use.
Supporting Evidence
- A recent shift in the drug product environment for Africa has created new challenges for regulators.
- 90% of MRAs in sub-Saharan Africa were found to be unable to adequately carry out regulatory functions.
- The study proposes six recommendations to create an efficient integrated system of drug approvals for Africa.
Takeaway
This study talks about how to help African regulators approve new medicines for diseases that mainly affect people in Africa, making sure they are safe and effective.
Methodology
The article discusses various regulatory pathways and proposes recommendations for improving drug registration in Africa.
Potential Biases
Potential bias due to reliance on Western regulatory standards that may not consider the specific needs of African populations.
Limitations
The current system of ND drug approval is inefficient and does not adequately meet Africa's needs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website